263 related articles for article (PubMed ID: 31562001)
1. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017.
Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Regan DG; Hocking JS; Garland SM; Cornall AM; Atchison S; Bradshaw CS; McNulty A; Owen L; Marshall L; Russell DB; Kaldor JM; Chen MY
Vaccine; 2019 Oct; 37(46):6907-6914. PubMed ID: 31562001
[TBL] [Abstract][Full Text] [Related]
2. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
3. Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program.
Machalek DA; Chow EP; Garland SM; Wigan R; Cornall AM; Fairley CK; Kaldor JM; Hocking JS; Williams H; McNulty A; Bell C; Marshall L; Ooi C; Chen MY; Tabrizi SN
J Infect Dis; 2017 Jan; 215(2):202-208. PubMed ID: 27815379
[TBL] [Abstract][Full Text] [Related]
4. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study.
Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Garland SM; Cornall AM; Atchison S; Hocking JS; Bradshaw CS; Balgovind P; Murray GL; Chen MY
Lancet Infect Dis; 2021 Oct; 21(10):1448-1457. PubMed ID: 34043963
[TBL] [Abstract][Full Text] [Related]
6. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
7. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
8. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
9. Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination.
Machalek DA; Garland SM; Brotherton JML; Bateson D; McNamee K; Stewart M; Rachel Skinner S; Liu B; Cornall AM; Kaldor JM; Tabrizi SN
J Infect Dis; 2018 Apr; 217(10):1590-1600. PubMed ID: 29425358
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
11. Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females.
Subasinghe AK; Wark JD; Phillips S; Cornall A; Brotherton JML; Garland SM
Sex Health; 2020 Dec; 17(6):510-516. PubMed ID: 33341122
[TBL] [Abstract][Full Text] [Related]
12. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
13. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA
Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743
[TBL] [Abstract][Full Text] [Related]
15. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
[TBL] [Abstract][Full Text] [Related]
16. HPV.edu study protocol: a cluster randomised controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescents.
Skinner SR; Davies C; Cooper S; Stoney T; Marshall H; Jones J; Collins J; Hutton H; Parrella A; Zimet G; Regan DG; Whyte P; Brotherton JM; Richmond P; McCaffrey K; Garland SM; Leask J; Kang M; Braunack-Mayer A; Kaldor J; McGeechan K
BMC Public Health; 2015 Sep; 15():896. PubMed ID: 26373926
[TBL] [Abstract][Full Text] [Related]
17. Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs.
Elfström KM; Lazzarato F; Franceschi S; Dillner J; Baussano I
J Infect Dis; 2016 Jan; 213(2):199-205. PubMed ID: 26142436
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of HPV After Introduction of the Vaccination Program in the United States.
Markowitz LE; Liu G; Hariri S; Steinau M; Dunne EF; Unger ER
Pediatrics; 2016 Mar; 137(3):e20151968. PubMed ID: 26908697
[TBL] [Abstract][Full Text] [Related]
19. Canadian school-based HPV vaccine programs and policy considerations.
Shapiro GK; Guichon J; Kelaher M
Vaccine; 2017 Oct; 35(42):5700-5707. PubMed ID: 28893472
[TBL] [Abstract][Full Text] [Related]
20. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.
Smith MA; Lew JB; Walker RJ; Brotherton JM; Nickson C; Canfell K
Vaccine; 2011 Nov; 29(48):9112-22. PubMed ID: 21419773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
